.png)
.png)
BioDivide Ltd Announces the Launch of the Next Generation Equine Stem Cell Therapy
MELKSHAM, England – 18 April 2019 BioDivide Limited (“BioDivide” or the “Company”) launches StemPlan® the next generation stem cell therapy for horses. Veterinarians are invited to attend CPD events to support the product launch. The first event to be held at The Company’s state-of-the-art manufacturing facility 1st May 2019 includes a presentation entitled “Innovations in Equine Regenerative Medicine” to be delivered by leading stem cell scientist Dr Erik Miljan and equine veterinarian and race horse trainer Dr Jeremy Naylor followed by a networking session.
The event will provide rich insights into the latest research and knowledge of how stem cells can be used to repair and regenerate damaged tissue in a range of equine indications. The event will also feature StemPlan, a BioDivide product that uses a non-invasive proprietary method of collecting stem cells. Not offered by any other company, StemPlan provides veterinarians with a standardised stem cell therapy product in a frozen ready-to-inject formulation.
“We are excited about the opportunity to engage directly with veterinarians to discuss the latest advances in equine regenerative medicine and provide comprehensive information about our exclusive products and services” said Dr Erik Miljan, BioDivide’s founder. “We believe that our facility is impressive and highlights our commitment to deliver the highest quality next generation stem cell product”, added Dr Miljan.
Jeremy Naylor stated the ability to isolate stem cells from peripheral blood and generate pure cell lines in measured doses is a major breakthrough in the development of regenerative medicine. “This will open the door to a much wider implementation of stem cell therapy in everyday equine practice for managing a wide range of clinical conditions” he said.
The event will provide rich insights into the latest research and knowledge of how stem cells can be used to repair and regenerate damaged tissue in a range of equine indications. The event will also feature StemPlan, a BioDivide product that uses a non-invasive proprietary method of collecting stem cells. Not offered by any other company, StemPlan provides veterinarians with a standardised stem cell therapy product in a frozen ready-to-inject formulation.
“We are excited about the opportunity to engage directly with veterinarians to discuss the latest advances in equine regenerative medicine and provide comprehensive information about our exclusive products and services” said Dr Erik Miljan, BioDivide’s founder. “We believe that our facility is impressive and highlights our commitment to deliver the highest quality next generation stem cell product”, added Dr Miljan.
Jeremy Naylor stated the ability to isolate stem cells from peripheral blood and generate pure cell lines in measured doses is a major breakthrough in the development of regenerative medicine. “This will open the door to a much wider implementation of stem cell therapy in everyday equine practice for managing a wide range of clinical conditions” he said.